Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:ACRS NASDAQ:GYRE NASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.36-1.5%$2.73$0.99▼$3.60$170.10M0.32678,759 shs101,939 shsACRSAclaris Therapeutics$4.80-0.1%$4.01$1.18▼$5.15$668.27M0.762.04 million shs135,014 shsGYREGyre Therapeutics$6.81-2.8%$7.46$6.57▼$11.67$661.26M2.0389,374 shs14,574 shsSTROSutro Biopharma$40.55+5.5%$28.84$6.74▼$43.85$660.83M1.63183,808 shs71,684 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-4.02%-3.24%-10.82%-4.78%+143.88%ACRSAclaris Therapeutics-5.70%-1.23%+22.45%+50.47%+306.78%GYREGyre Therapeutics-3.85%-0.99%-10.71%-12.72%-32.63%STROSutro Biopharma-2.98%-3.54%+33.50%+137.75%+424.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.36-1.5%$2.73$0.99▼$3.60$170.10M0.32678,759 shs101,939 shsACRSAclaris Therapeutics$4.80-0.1%$4.01$1.18▼$5.15$668.27M0.762.04 million shs135,014 shsGYREGyre Therapeutics$6.81-2.8%$7.46$6.57▼$11.67$661.26M2.0389,374 shs14,574 shsSTROSutro Biopharma$40.55+5.5%$28.84$6.74▼$43.85$660.83M1.63183,808 shs71,684 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-4.02%-3.24%-10.82%-4.78%+143.88%ACRSAclaris Therapeutics-5.70%-1.23%+22.45%+50.47%+306.78%GYREGyre Therapeutics-3.85%-0.99%-10.71%-12.72%-32.63%STROSutro Biopharma-2.98%-3.54%+33.50%+137.75%+424.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 2.50Moderate Buy$6.67183.09% UpsideACRSAclaris Therapeutics 3.00Buy$11.29135.36% UpsideGYREGyre Therapeutics 2.00Hold$17.00149.78% UpsideSTROSutro Biopharma 2.85Moderate Buy$43.787.97% UpsideCurrent Analyst Ratings BreakdownLatest ABOS, GYRE, ACRS, and STRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026STROSutro Biopharma Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$43.005/15/2026STROSutro Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $50.005/11/2026GYREGyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/8/2026STROSutro Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/4/2026STROSutro Biopharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/1/2026STROSutro Biopharma Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/30/2026STROSutro Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$50.004/30/2026STROSutro Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$50.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$1.21 per shareN/AACRSAclaris Therapeutics$7.83M85.53N/AN/A$1.03 per share4.66GYREGyre Therapeutics$116.59M5.66$0.21 per share32.76$1.41 per share4.83STROSutro Biopharma$102.48M6.56N/AN/A($15.43) per share-2.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$121.33M-$2.01N/AN/AN/AN/A-123.07%-79.41%N/AACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%N/AGYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.13%2.67%N/ASTROSutro Biopharma-$191.09M-$26.10N/AN/AN/A-186.45%N/A-79.02%N/ALatest ABOS, GYRE, ACRS, and STRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026STROSutro Biopharma-$2.7363-$2.94-$0.2037-$2.94$8.89 million$14.52 million5/12/2026Q1 2026ABOSAcumen Pharmaceuticals-$0.4028-$0.33+$0.0728-$0.33N/AN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million3/26/2026Q4 2025ABOSAcumen Pharmaceuticals-$0.50-$0.41+$0.09-$0.41N/AN/A3/12/2026Q4 2025GYREGyre Therapeutics$0.08$0.04-$0.04-$0.02$36.30 million$37.20 million2/26/2026Q4 2025ACRSAclaris Therapeutics-$0.15-$0.1614-$0.0114-$0.16$2.07 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AACRSAclaris TherapeuticsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.194.554.07ACRSAclaris TherapeuticsN/A4.034.03GYREGyre TherapeuticsN/A4.645.04STROSutro BiopharmaN/A2.012.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%ACRSAclaris Therapeutics98.34%GYREGyre Therapeutics23.99%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%ACRSAclaris Therapeutics5.60%GYREGyre Therapeutics10.00%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2072.23 million65.51 millionOptionableACRSAclaris Therapeutics100139.66 million131.84 millionOptionableGYREGyre Therapeutics4097.03 million87.33 millionNo DataSTROSutro Biopharma24016.57 million15.97 millionOptionableABOS, GYRE, ACRS, and STRO HeadlinesRecent News About These CompaniesSutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsMay 14 at 4:05 PM | globenewswire.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 7, 2026 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Moderate Buy" by AnalystsMay 7, 2026 | marketbeat.comSutro Biopharma (STRO) Expected to Announce Earnings on ThursdayMay 7, 2026 | americanbankingnews.comSutro Biopharma (STRO) to Release Earnings on ThursdayMay 7, 2026 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Truist FinancialMay 6, 2026 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Sets New 1-Year High - Still a Buy?May 5, 2026 | marketbeat.comLifesci Capital Forecasts Sutro Biopharma Q1 EarningsMay 5, 2026 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Upgraded at Lifesci CapitalMay 2, 2026 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Upgraded by Mizuho to "Strong-Buy" RatingMay 1, 2026 | marketbeat.comCitizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead ProgramMay 1, 2026 | insidermonkey.comMizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendationMay 1, 2026 | msn.comSutro Biopharma: Recycling Past Data Ahead Of The Readout, SellMay 1, 2026 | seekingalpha.comShort Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Grows By 17.0%April 30, 2026 | marketbeat.comHere is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right NowApril 29, 2026 | finance.yahoo.comSutro Biopharma (NASDAQ:STRO) Hits New 1-Year High - What's Next?April 29, 2026 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Shares Up 5.6% - What's Next?April 28, 2026 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Shares Gap Down - What's Next?April 27, 2026 | marketbeat.comSutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - SlideshowApril 24, 2026 | seekingalpha.comSutro Biopharma (NASDAQ:STRO) Shares Down 6.1% - Time to Sell?April 24, 2026 | marketbeat.comCitizens Jmp Boosts Sutro Biopharma (NASDAQ:STRO) Price Target to $41.00April 23, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20263 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026Wall Street Loves TJX, But Is the Stock Still a Good Deal for Investors?By Jennifer Ryan Woods | May 3, 2026Hilton’s Q1 Report Put One Big Question Front and Center for 2026By Chris Markoch | April 30, 2026MarketBeat Week in Review – 04/27 - 05/01By MarketBeat Staff | May 2, 2026ABOS, GYRE, ACRS, and STRO Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$2.36 -0.04 (-1.46%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Aclaris Therapeutics NASDAQ:ACRS$4.80 -0.01 (-0.10%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Gyre Therapeutics NASDAQ:GYRE$6.81 -0.19 (-2.77%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Sutro Biopharma NASDAQ:STRO$40.54 +2.13 (+5.53%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
